Abstract
We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm3) during 1994-1996. FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (≥200 mg) of fluconazole. Thirty-six persons (4.3%) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was
| Original language | English (US) |
|---|---|
| Pages (from-to) | 749-756 |
| Number of pages | 8 |
| Journal | Clinical Infectious Diseases |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2000 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. / Fichtenbaum, C. J.; Koletar, S.; Yiannoutsos, Constantin; Holland, F.; Pottage, J.; Cohn, S. E.; Walawander, A.; Frame, P.; Feinberg, J.; Saag, M.; Van der Horst, C.; Powderly, W. G.
In: Clinical Infectious Diseases, Vol. 30, No. 5, 2000, p. 749-756.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Refractory mucosal candidiasis in advanced human immunodeficiency virus infection
AU - Fichtenbaum, C. J.
AU - Koletar, S.
AU - Yiannoutsos, Constantin
AU - Holland, F.
AU - Pottage, J.
AU - Cohn, S. E.
AU - Walawander, A.
AU - Frame, P.
AU - Feinberg, J.
AU - Saag, M.
AU - Van der Horst, C.
AU - Powderly, W. G.
PY - 2000
Y1 - 2000
N2 - We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm3) during 1994-1996. FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (≥200 mg) of fluconazole. Thirty-six persons (4.3%) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was
AB - We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm3) during 1994-1996. FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (≥200 mg) of fluconazole. Thirty-six persons (4.3%) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was
UR - http://www.scopus.com/inward/record.url?scp=0033807041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033807041&partnerID=8YFLogxK
U2 - 10.1086/313765
DO - 10.1086/313765
M3 - Article
C2 - 10816143
AN - SCOPUS:0033807041
VL - 30
SP - 749
EP - 756
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 5
ER -